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INTRODUCTION
In the last decade, the H. 
pylori eradication rate following 
standard 7-day triple therapies 
has fallen to unacceptably low 
cure rates worldwide [1]. This 
has been largely attributed to the 
increased prevalence of primary 
resistance towards clarithromycin 
and metronidazole, widely used 
for H. pylori treatment [2, 3]. 
Therefore, current European 
guidelines suggest the use of a 
prolonged 10-14 days first-line 
triple therapy in those areas 
where primary clarithromycin 
resistance is >15-20% [4]. In 
addition, the use of high-dose 
(twice daily) proton pump 
inhibitor (PPI) should be 
considered to further increase 
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ABSTRACT
Background & Aims: The updated Italian guidelines advise a standard 14-day triple therapy for first-line H. 
pylori eradication. This prospective study evaluated the cure rate following a 14-day triple therapy with either 
a standard or double-dose proton pump inhibitor (PPI). 
Methods. A total of 145 consecutive patients with H. pylori infection were randomized to receive a 14-day, 
first-line triple therapy with clarithromycin 500 mg, amoxicillin 1 g and esomeprazole at either 20 mg (standard 
therapy) or 40 mg (double-dose therapy), each given twice daily. 
Results. At intention-to-treat analysis, H. pylori infection was cured in 73.9% (95% CI: 63.9−84) and 81.9% 
(95% CI: 73−90.8) following standard and double-dose therapy, respectively, and in 78.2% (95% CI: 68.5−87.9) 
and 85.5% (95% CI: 77.2−93.8) at per-protocol analysis. No statistically significant difference occurred. Overall, 
16.4% and 19.4% patients in the standard and double-dose therapy regimen complained of side effects. 
Conclusion. The success rate of both standard and double-dose 14-day triple therapies for first-line H. pylori 
treatment was unsatisfactory. A prolonged 14-day levofloxacin-based triple therapy for second-line H. pylori 
eradication seems to be promising.          
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the efficacy of triple therapy [4]. The updated Italian guidelines 
advise a standard 14-day triple therapy for first-line H. pylori 
eradication [5]. However, following such a therapy, a cure 
rate less than the auspicated 90% was observed in some trials 
[6-8]. To our knowledge, no study has evaluated the efficacy 
of a 14-day triple therapy including double-dose PPI in Italy. 
We therefore designed a prospective study to evaluate the cure 
rate following a 14-day triple therapy with either standard or 
double-dose PPI in a central-southern Italian region with a 
high prevalence of clarithromycin resistance. As a secondary 
aim, the efficacy of a 14-day, levofloxacin-based triple therapy 
for second-line treatment in the eradication failure patients 
was tested.
MATERIAL AND METHODS
Patients
Consecutive patients complaining of dyspeptic symptoms 
referred for upper endoscopy in the participating three centres 
(Foggia, Rome, Latina) were considered for recruitment into 
the study. Exclusion criteria were: 1) age <18 years; 2) previous 
eradication therapy failures; 3) consumption of PPI and/or 
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antibiotics in the previous two months; 4) previous gastric 
surgery; 5) liver cirrhosis or kidney failure, alcohol abuse, 
pregnancy, and known allergy to antibiotics. For all patients 
an informed consent was obtained.
Endoscopy and H. pylori detection
All patients underwent upper endoscopy, and five gastric 
biopsies were taken according to the updated Sydney System 
[9]. H. pylori infection was considered present when bacteria 
together with an active chronic gastritis were detected at 
histology, on Eosin & Hematoxylin staining and modified 
Giemsa staining in doubtful cases, as performed in clinical 
practice. The presence of a peptic ulcer was defined as mucosal 
ulceration >5 mm in diameter. For the purpose of the study, 
patients with duodenal or gastric ulcer were considered 
as having peptic ulcer disease (PUD), while those without 
macroscopic mucosal abnormalities were considered as non-
ulcer dyspeptic patients (NUD). Bacterial eradication was 
checked 6–8 weeks following therapy by using a standard 
13C-urea breath test (UBT) with a cut-off value of 3.5%, 
according to the manufacturer’s recommendations. The UBT 
control was performed in laboratories not involved in the study. 
Therapy regimens
This was a prospective, open-label, randomized study. 
Patients were randomized by a computer-generated list to 
receive a 14-day triple therapy with clarithromycin 500 mg, 
amoxicillin 1 g and esomeprazole at either 20 mg or 40 mg 
dose. All drugs were given twice daily, with PPI given half-hour 
before breakfast and dinner, and antibiotics following these 
meals. Patients were thoroughly instructed and motivated to 
the therapy. At the end of the treatment, both side effects and 
therapeutic compliance were assessed by personal interview. 
A pill intake >90% was considered as good compliance. When 
first-line therapy failed, a second-line therapy regimen with 
esomeprazole 20 mg, amoxicillin 1 g, and levofloxacin 250 
mg, all twice daily, was administered for 14 days. The cost of 
therapies was calculated based on number of tablets required 
for the entire treatment by including only brand drugs. 
Statistical analysis
Comparisons between patient groups were performed by 
using the T-test for unpaired data and the Chi-square test, as 
appropriate. The eradication rates with their 95% confidence 
intervals (CIs) were calculated at both ‘intention-to-treat’ (ITT) 
and at ‘per protocol’ (PP) analyses. At ITT all the enrolled 
patients were included, whilst at PP only compliant patients 
who underwent UBT control were considered. Before pooling 
data, the observed eradication rates were compared to exclude 
a statistically significant difference among centres. Differences 
were considered significant at a 5% probability level. SPSS was 
used for statistical analysis.
RESULTS
One-hundred and forty-five patients were enrolled from 
January to November 2015, including 73 and 72 patients in the 
standard and double-dose therapy regimen, all included at ITT 
analysis. A total of 7 patients were considered drop-outs due 
to either early therapy interruption for side-effects (3 cases) 
or because they had failed to attend the UBT control (4 cases). 
Therefore, there were 69 and 69 patients at PP analysis. No 
statistically significant differences were present between the 
two groups at entry, except of a higher prevalence of females 
in the standard regimen (Table I). Overall, 12 (16.4%) and 
14 (19.4%) patients in the standard and double-dose therapy 
regimen complained of side-effects, including abdominal pain/
nausea (12), mild diarrhoea (11),  metallic taste (3), itching (2), 
and urticaria (1). In 3 cases, the therapy was earlier stopped 
(at 3, 10 and 12 days).
As shown in Table II, the cure rate following the double-
dose PPI regimen was higher than the standard-dose at both 
ITT (+8%) and PP (+7.3%), although the differences were not 
statistically significant. Moreover, only for the double-dose 
regimen the high 95% CI limit was superior to 90%, at both ITT 
and PP analysis. By considering all the 145 patients included 
in the PP analysis, the eradication rate tended to be lower in 
PUD than in NUD patients (69.2% vs 83.2%), whilst similar 
cure rates occurred in males and females (82.4% vs 81.4%), as 
well as in smokers and no smokers (81.3% vs 82.1%). In Italy, 
the cost of treatment was 44.82 and 54.71 Euros for standard 
and double-dose PPI regimen, respectively. 
Table II. H. pylori eradication rates.
Eradication rate Standard-dose 
PPI
Double-dose 
PPI
P value
ITT analysis; N 
(%; 95%CI)
54/73
(73.9; 63.9−84)
59/72
(81.9; 73−90.8)
0.25
PP analysis; N 
(%; 95%CI)  
54/69  
(78.2; 8.5−87.9)
59/69 
(85.5; 7.2−93.8)
0.27
A total of 16 out of 25 eradication failure patients agreed 
to perform the second-line levofloxacin-based triple therapy. 
The infection was cured in 14 (87.5%; 95%CI 71.3-100). 
Compliance was good in all these patients, and side-effects 
occurred in 3 (18.7%) cases, including mild diarrhoea (2 
patients) and itching (1 patient). 
DISCUSSION
Standard triple therapies remain the mostly used first-
line treatment for H. pylori eradication in clinical practice. 
Unfortunately, the success rate following either 7-10 days triple 
Table I. Demographic and clinical characteristics of the enrolled 
patients.
Standard-dose 
PPI
High-dose 
PPI
P Value
Number of patients 73 72 -
Age (mean±SD) years 51.2 ± 14.2 47.9 ± 15.8 0.3
Sex male/female 21/52 32/40 0.0499
Smoking habit (Yes/No) 16/57 25/47 0.12
Disease: NUD/PUD 64/9 68/4 0.25
PPI: proton pump inhibitor; NUD: non-ulcer dyspepsia; PUD: peptic 
ulcer disease. 
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therapies has declined to unacceptably low values in Italy [10], 
and several factors have been advocated as potential causes 
of therapy failure [11]. Therefore, the current European and 
Italian guidelines have suggested prolonging to 14 days the 
standard triple therapy duration in those areas with a high 
prevalence of primary clarithromycin resistance [4, 5]. Indeed, 
it has been found that a longer triple therapy significantly 
increased the cure rate as compared to the 7-10 days regimen 
[12-16]. The use of increased PPI doses is another suggestion 
to improve the cure rate of triple therapies [4]. In Southern and 
Central Italy, where this study was performed, the prevalence 
rate of primary clarithromycin resistance has been found to 
be higher than 20% [17, 18].  Based on these observations, we 
peformed this study to test the efficacy of 14-day triple therapy 
with either standard or double PPI doses for first-line H. pylori 
eradication. Our data found that both these triple therapies 
achieved unsatisfactory eradication rates, with values <80% 
at ITT analysis. In detail, the cure rate following the standard 
14-day triple therapy regimen was consistent to 70-81.7% 
eradication rates achieved in other Italian studies [5-8], as 
well as to 74.8-82.2% observed in other countries, such as 
Germany, Korea, and Latin America [10, 19]. Following the 
14-day triple therapy with double-dose PPI we observed a trend 
towards increased (7-8%) eradication rates when compared to 
the standard regimen. However, even following this therapy 
the cure rate was 81.9-85.5%. To our knowledge, the efficacy 
of this therapy regimen has been tested only in another study 
recently performed in Spain, where the eradication rates were 
81.3-82.3% [20]. Although modest, such a therapeutic gain 
in the presence of high clarithromycin resistance is probably 
clinically advantageous when considering that the cost of 
therapy, in Italy, is increased by only 10 Euros. 
According to current guidelines [4, 5] we administered a 
levofloxacin-based triple regimen as a second-line therapy. 
Since we previously found that the cure rate following a 
standard 10-day regimen is decreasing, with an eradication 
rate ranging from to 55.6% to 72.6% [21-23], a 14-day therapy 
was chosen. Worth noting is that such a therapy achieved 
an encouragingly high (87.5%) eradication rate. A similarly 
prolonged levofloxacin-based triple, with double-dose PPI, 
achieved 84.8-93.6% success rates in Taiwan [24, 25]. However, 
when a regimen with increased doses was administered for 
only 8 days, the eradication rate was only 60-64% [26]. These 
observations suggest that the therapy duration of levofloxacin-
based second-line therapy should be prolonged to 14 days 
rather than increasing the drugs dosage. Further studies are 
required to confirm these results. On the other hand, the three-
in-one pill, bismuth-based therapy could be useful as a rescue 
therapy, and its commercialization is awaited in our country.
CONCLUSION 
The standard 14-day triple therapy seems to be unsuccessful 
for first-line H. pylori treatment in those areas with a high 
primary clarithromycin resistance, such as in Italy. Whether 
a double-dose PPI regimen is able to significantly increase 
the success rate needs to be proven in further studies. The 
efficacy of prolonged 14-day levofloxacin-based triple therapy 
for second-line H. pylori eradication seems to be promising.    
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